# Willem â€” Health Context

## Profile
- Age 22, 6'1", ~145 lbs (underweight, lost 10 lbs)
- Columbus, Ohio. Manages roofing company backend + multiple businesses.
- Communication: Direct, no fluff, analytical. Responds well to being pushed.

## Diagnoses
- H. pylori (GI-MAP 3.53e3, clarithromycin resistant, no virulence factors)
- IMO (breath test CH4 12.64, threshold <10)
- Severe dysbiosis (Pseudomonas 17x, Staph 5.6x, Streptococcus 92x, Enterobacter 3.7x)
- Mucosal immune hyperactivation (sIgA 3253, ref 510-2010)
- Suspected secondary MCAS (pending tryptase)

## Active Protocols
- Phase 0 of 7-phase recovery (started Feb 14, 2026)
- H1/H2 blockers: Cetirizine 10mg AM + Famotidine 20mg BID
- Peptides: CJC/Ipa titrating to 200/200mcg, GHK-Cu titrating to 2mg
- BPC-157 gated behind tryptase (VEGF/mast cell risk)
- Bismuth quadruple therapy upcoming (14 days)

## Key Decisions
- BPC-157 gated: VEGF upregulation risk with mast cells
- GHK-Cu pauses during bismuth therapy: copper-bismuth competition
- Bismuth quad chosen over triple therapy: clarithromycin resistant
